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Abstract
Microcystins are potent phosphatase inhibitors and cellular toxins. They require active transport by OATP1B1 and OATP1B3
transporters for uptake into human cells, and the high expression of these transporters in the liver accounts for their
selective hepatic toxicity. Several human tumors have been shown to have high levels of expression of OATP1B3 but not
OATP1B1, the main transporter in liver cells. We hypothesized that microcystin variants could be isolated that are
transported preferentially by OATP1B3 relative to OATP1B1 to advance as anticancer agents with clinically tolerable hepatic
toxicity. Microcystin variants have been isolated and tested for cytotoxicity in cancer cells stably transfected with OATP1B1
and OATP1B3 transporters. Microcystin variants with cytotoxic OATP1B1/OATP1B3 IC50 ratios that ranged between 0.2 and
32 were found, representing a 150-fold range in transporter selectivity. As microcystin structure has a significant impact on
transporter selectivity, it is potentially possible to develop analogs with even more pronounced OATP1B3 selectivity and
thus enable their development as anticancer drugs.
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Introduction
Microcystins (MCs) are cyclic heptapeptides produced by
several cyanobacterial genera such as Microcystis, Oscillatoria,
Planktothrix, Nostoc, and Anabaena. They can be considered to be
among the best studied cyanobacterial secondary metabolites [1–
4]. The common structural feature of microcystins is a polyketide
synthase derived amino acid with the acronym ‘‘Adda’’,
(2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-
4,6-dienoic acid, which is also one of the two mandatory
substructures for the potent protein serine/threonine phosphatase
(PP) 1 and PP2A inhibition observed for the microcystins [5–9].
Not only is the biosynthesis of these compounds by polyketide
synthases and non-ribosomal peptide synthetases remarkably well
understood [10–12], but also more than 90 individual members of
this chemically highly diverse compound family have been
described in the scientific literature to date (Fig. 1) [13–56].
Especially prone to variation are the L-amino acids situated at
positions 2 and 4 of the MC backbone. Related compounds are
the nodularins, found in Nodularia sp., which also contain Adda but
are cyclic pentapeptides instead of heptapeptides (Fig. 1) [57–60].
Being potent protein serine/threonine phosphatase inhibitors,
microcystins and nodularins have a profound effect on cell
signaling and cytoskeleton maintenance, leading to the death of
affected cells [61,62]. However, the relatively large and amphi-
philic MCs are unable to cross cell membranes by passive
diffusion. Instead, they rely on active uptake by cells. Three
members of the organic anion transporting polypeptides (OATP)
family are able to mediate this uptake of MCs, namely OATP1B1,
1B3 and 1A2 [63,64]. OATP1B1 and OATP1B3 are the most
efficient microcystin transporters, and as in healthy humans both
transporters are exclusively found to be expressed in liver tissue
[64,65], microcystins and nodularins are known to cause extensive
liver damage [66–68]. Thus microcystins became infamous as
hepatotoxins causing harm to humans and cattle when these
compounds accumulated in sources of drinking water during algal
water bloom times [69,70]. Inhibitors of these OATP transporters
ameliorate the hepatotoxicity of microcystins and nodularins
[68,71,72]. In contrast to OATP1B1, which is expressed in
hepatocytes throughout the liver lobe, OATP1B3 localization is
restricted around the central vein [64].
OATPs are currently in discussion as targets for cancer therapy
[73–76]. Most interestingly, OATP1B3, but not OATP1B1, has
been found to be functionally expressed in a number of cancer
tissues, especially colon tumors, but also breast tumors, lung
tumors, pancreatic and hepatocellular tumors [75,77–79]. As
differential toxicity of natural microcystin variants on cell lines
expressing either OATP1B1 or OATP1B3 has been observed
[78,80], these findings raised the question whether microcystins
might be suitable as leads for drug substances against these cancer
types, and if there are microcystins among the more than 90
known variants that are selectively transported by OATP1B3
relative to OATP1B1. Selectivity that favors OATP1B3 over
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OATP1B1 should lead to a decreased hepatic clearance and
increased uptake of MCs in OATP1B3-expressing tumors,
creating a therapeutic window of the respective compound by
decreasing the hepatic clearance rate and toxicity. MCs are
interesting as novel lead structures because they have a mode of
action not yet used but currently discussed for cancer therapy
(phosphatase inhibition) [81–83], and in contrast to the majority of
currently available anticancer drugs, they need active transport
into cells and thus spare all tissues not expressing the mentioned
OATPs.
We have isolated various microcystin congeners from cyano-
bacteria of the genera Microcystis, Planktothrix, and Nodularia to test
the hypothesis whether different transporter selectivities might be
attainable. As tools for selectivity testing, cervical cancer HeLa
cells and colon cancer RKO cells stably transfected with
expression vectors for OATP1B1 and 1B3 have been used. In
the present manuscript, the results of the testing of isolated MCs
on these cell lines are described. The determined IC50 values as
well as the observed selectivity differences clearly show that small
structural differences of the tested MCs indeed have a significant
impact on transporter selectivity and cytotoxic potency.
Results and Discussion
The amino acid (AA) compositions of the tested MCs are
summarized in Table 1
The structures of the microcystin congeners have been
determined based on tandem HRMS [51,52,84], supported by
1H- and COSY-NMR spectroscopy. All MCs contain the
characteristic Adda moiety at position 5 and D-Ala at position 1
of the molecule. Only one of the isolated congeners features an O-
methylated D-iso-Glu instead of D-iso-Glu at position 6 (22). D-iso-
b-MeAsp and D-iso-Asp in position 3 are almost equally
distributed, as are Mdha and Dhb in position 7. The L amino
acids in position 2 comprise Leu, Tyr, Arg, Hty, Hil (descending
order of count), in position 4 Arg, Tyr, Trp, Phe, Hty, and Har are
found. In addition to 22 MC variants, nodularin (23) as a cyclic
Adda containing pentapeptide as well as okadaic acid (24) as a
structurally not MC-related PP inhibitor have been tested.
The IC50 values of all isolated MCs against OATP1B1- and
OATP1B3-expressing HeLa or RKO cell lines have been
determined. The results are shown in Table 2.
Interestingly, marked differences for both potency and selectiv-
ity of the individual MC congeners could be observed.
Selectivity
While substitution of D-iso-b-MeAsp3 for D-iso-Asp3 (e.g.
compounds 1/2 and 13/14) seems not to have a significant
influence on neither potency nor selectivity, the influence of the
presence of either Mdha7 or (E)-Dhb7 (e.g. 3/4, 5/6, 8/9, and
14/15) is ambiguous: While in the case of 3/4 and 5/6
substitution of Mdha7 for (E)-Dhb7 lead to a profound increase
in selectivity for OATP1B3 over OATP1B1, this effect was not
observed for 8/9 and 14/15. As the six least OATP1B3 selective
compounds (1, 2, 3, 5, 7, 23) all feature Mdha7 or Mdhb7 while
(E)-Dhb7 is found in 3 of the 6 most OATP1B3 selective
compounds (4, 10, 12, 15, 16, 18), it is likely that (E)-Dhb7 has
an influence in selectivity but is not the only structural feature
conferring selectivity.
Indeed, especially the amino acid residues at positions 2 and 4 of
the MC core structure seem to be important for both potency and
selectivity. While 80% of the most OATP1B1 selective compounds
feature Leu at position 2, this amino acid is completely absent in
the most OATP1B3 selective compounds. However, Leu is also
found in position 2 of several congeners that are weakly OATP1B3
selective (6, 8, 9), thus Leu alone does not make a compound
OATP1B1 selective. Arg in position 2 seems to induce OATP1B3
selectivity, while Arg in position 4 does not have any influence on
selectivity. This is obvious with compounds 13 and 16, where
exchange of the amino acids in positions 2 and 4 has a huge
impact on selectivity. Arg in combination with the aromatic amino
acids Phe, Tyr, and Hty are prominent monomers found in
OATP1B3 selective compounds. Especially combinations of Arg2
and Phe4 (12) or Arg2 and Tyr4 (16) seem to confer OATP1B3
selectivity. But again, presence of Arg in position 2 seems not to be
mandatory for OATP1B3 selectivity (4).
Interestingly, the pentapeptide Nodularin (23) is the most
OATP1B1 selective among the Adda containing compounds
examined.
Potency
Potency of MC induced cell death in the test system used for this
study has two facets. On one hand, toxicity of MC congeners
depends on the extent of their PP inhibition [85]. On the other
Figure 1. General structures of microcystins and nodularins. Prevalence of residues found within microcystins (left) and nodularins (right) is
proportional to the font size of the respective residue. Data used to generate this figure is deposited at http://dx.doi.org/10.6084/m9.figshare.880756.
doi:10.1371/journal.pone.0091476.g001
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hand, potency is depending on transporting capacity of the
respective OATP. These two effects have not been distinguished in
the present study. While some previous studies suggest that in vitro
and in vivo toxicity are related to enzyme inhibition rather than
transport [78,85], other reports show comparable PP inhibition of
different microcystin congeners, implying that differences in
transport contribute to in vivo toxicity [80,86].
Not surprisingly, 22, featuring O-methylated D-iso-Glu6, is one
of the least potent compounds. Modifications of the free carboxylic
acid of Glu are likely to lead to a loss of efficiency due to loss of
interaction with a positively charged arginine in the active center
of the protein phosphatases [7], and Glu(OMe) containing
congeners have been found to inhibit PP1 to a much lesser extent
than analogous Glu containing MCs [87] and have lower in vivo
toxicity [26]. Interestingly, also 10, 11 and 21 displayed weaker
toxicity than most other congeners. While 10 inhibits PP2A about
twenty times weaker compared with 1 [78,80,85,86], its toxicity in
the present assay is about 500 times lower. This indicates that in
the case of 10 (and also its analog 11), it is probable that toxicity is
not only a matter of PP inhibition efficiency, but also of OATP
transporting capability, as MC-RR is a dication under physiolog-
ical conditions and thus less likely to be transported across cell
membranes by anion transporters. In general, cytotoxicity in our
assay does not correlate with protein phosphatase inhibition
potency as described in the literature for compounds 1, 2, 6, 7, 8,
9, 10, 13, 18, 19, 20, 23 [56,78,80,85,86]. Our data thus indicate
that differing transport efficiencies have a higher impact on in vivo
toxicity than differing protein phosphatase inhibition potency.
Interestingly, the most potent MCs, with IC50 values in the sub-
nanomolar range (5, 6, 7, 8, 17, 18, 19), all feature combinations
of either Leu2 and Tyr/Phe/Trp4 or Tyr/Hty2 and Tyr/Hty4.
Arg is absent from the most potent congeners. The least potent
congeners with IC50 values . 100 nM (10, 11, 21, 22) all feature
either Tyr2 and Arg/Har4 or Arg2 and Arg4. Presence of Arg in
general lowers the potency, again supporting the hypothesis that
the positively charged Arg residues hamper transport efficiency in
addition to reducing PP2A inhibition, and thus lower in vivo
toxicity.
Summary and Conclusions
In our screening of 23 natural MC variants, we have found
several MCs with an IC50 in the low nanomolar range and with
transporter selectivity that favors OATP1B3 over OATP1B1 by a
factor of up to thirty. While the presence of Arg in general lowers
the potency of MC cytotoxicity, its presence in position 2 of the
MC core structure also seems to be important for OATP1B3
selectivity, implying that this transporter might be more tolerant to
the cationic nature of Arg under physiological conditions than
OATP1B1. Furthermore, the presence of the slightly acidic
aromatic amino acids Tyr or Hty in position 4 in addition to
Arg in position 2 seems beneficial for OATP1B3 selectivity.
Table 1. Structures of the tested MC congeners originating from aMicrocystis aeruginosa, bPlanktothrix rubescens, and cNodularia
sp.
MC Congener AA 1 AA 2 AA 3 AA 4 AA 5 AA 6 AA 7
1a MC-LR Ala Leu MeAsp Arg Adda Glu Mdha
2a [D-Asp3]MC-LR Ala Leu Asp Arg Adda Glu Mdha
3a [D-Asp3]MC-HilR Ala Hil Asp Arg Adda Glu Mdha
4b [D-Asp3,(E)-Dhb7]MC-HilR Ala Hil Asp Arg Adda Glu Dhb
5a MC-LY Ala Leu MeAsp Tyr Adda Glu Mdha
6b [D-Asp3,(E)-Dhb7]MC-LY Ala Leu Asp Tyr Adda Glu Dhb
7a LF Ala Leu MeAsp Phe Adda Glu Mdha
8a LW Ala Leu MeAsp Trp Adda Glu Mdha
9b [D-Asp3,(E)-Dhb7]-MC-LW Ala Leu Asp Trp Adda Glu Dhb
10a RR Ala Arg MeAsp Arg Adda Glu Mdha
11b [D-Asp3,(E)-Dhb7]MC-RR Ala Arg Asp Arg Adda Glu Dhb
12a MC-RF Ala Arg MeAsp Phe Adda Glu Mdha
13a YR Ala Tyr MeAsp Arg Adda Glu Mdha
14a [D-Asp3]MC-YR Ala Tyr Asp Arg Adda Glu Mdha
15b [D-Asp3,(E)-Dhb7]MC-YR Ala Tyr Asp Arg Adda Glu Dhb
16a MC-RY Ala Arg MeAsp Tyr Adda Glu Mdha
17a MC-YY Ala Tyr MeAsp Tyr Adda Glu Mdha
18b [D-Asp3,(E)-Dhb7]MC-HtyY Ala Hty Asp Tyr Adda Glu Dhb
19b [D-Asp3,(E)-Dhb7]MC-HtyHty Ala Hty Asp Hty Adda Glu Dhb
20b [D-Asp3,(E)-Dhb7]MC-HtyW Ala Hty Asp Trp Adda Glu Dhb
21a [D-Asp3,MSer7]MC-YHar Ala Tyr Asp Har Adda Glu Mser
22a [D-Glu(OMe)6]MC-YR Ala Tyr MeAsp Arg Adda Glu(OMe) Mdha
23c Nodularin MeAsp Arg Adda Glu Mdhb
Hil homoisoleucine, Hty homotyrosine,MeAsp b-methylaspartic acid, Har homoarginine,Mdha N-methyl dehydroalanine, Dhb dehydrobutyric acid, Mser N-methyl
serine, Mdhb N-methyl dehydrobutyric acid.
doi:10.1371/journal.pone.0091476.t001
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Further studies are needed to discriminate whether the observed
differences in potency are due to differing PP inhibition or
different transport capability of the OATP. However, earlier
findings suggest that in vivo toxicity is mainly depending on OATP
transport kinetics than on differences in PP inhibition [80,86].
Although the deduced structure activity relationships are
ambiguous in parts, the structural features observed for OATP1B3
selectivity can be condensed to the at present most likely selective
general structure cyclo(-D-Ala1-L-Arg2-D-(Me)Asp3-L-aromatic
amino acid4-Adda5-D-Glu6-(E)-Dhb7). This general structure can
be used as a starting point for generating novel compounds e.g. by
precursor feeding or biocombinatorial strategies.
A challenge of using MCs as drug leads still remains: Even with
selective MC variants, liver toxicity still might be a significant
challenge, making it necessary to generate MC variants that could
be metabolically detoxified by healthy liver cells and/or efficiently
effluxed into the bile, and thus take advantage of hepatic
detoxification and clearance mechanisms that would not be found
in tumors.
Materials and Methods
Cyanobacterial Material
Several Microcystis aeruginosa and Planktothrix rubescens strains as
well as a Nodularia strain have been used to produce the studied
microcystin congeners: 2 and 3, Microcystis aeruginosa CBT 265; 4
and 15, Planktothrix rubescens CBT 310; 5, 16, and 17, Microcystis
aeruginosa CBT 850, 6, 9, 18, 19, and 20, Planktothrix rubescens CBT
862, 11, Planktothrix rubescens CBT 329, 12, Microcystis aeruginosa
CBT 861, 14, 21, and 22, Microcystis aeruginosa CBT 480, 23,
Nodularia sp. CBT 786. The strains were classified on the basis of
PCR analysis and sequencing of various marker genes as well as
their morphology, and have been deposited in the Cyano Biotech
(CBT) culture collection under the accession numbers indicated
above (Cyano Biotech, Berlin, Germany). The strains were
cultivated in BG11 medium [88] at 20uC under continuous light
(60-80 mmol m-2 s-1) in 20 L scale photobioreactors and harvested
semi-continuously over a period of several weeks.
Isolation of microcystins
Cyanobacteria strains were screened by HPLC-DAD/IT-TOF-
MS (Kinetex C18, 2.6 mm, 10063 mm column, phenomenex,
Torrance, USA) using a linear scouting gradient of aqueous
CH3CN (5 to 80% within 25 min at 0.6 ml/ min; 0.025% v/v
TFA) to confirm MC presence by their characteristic UV
spectrum as well as the characteristic tandem MS fragment ion
at m/z 375 [52,89]. Selected positive strains have been cultivated
in BG11 medium [88] at 20uC under continuous light (60-
80 mmol m-2 s-1) in 20 L scale photo bioreactors. After biomass
harvest and freeze-drying, the biomasses were resuspended in 50%
Table 2. IC50 values of MC congeners (1-23) and okadaic acid (24) against stably transfected HeLa or RKO cell lines expressing
either OATP1B1 or OATP1B3.
IC50 (nM) Ratio IC50 B1/B3
HeLa Control HeLa B1 HeLa B3 RKO control RKO B1 RKO B3 HeLa RKO
1 .1000 1 5.1 .1000 8.2 26.9 0.2 0.3
2 .1000 7.3 31.3 0.2
3 .1000 57.05 142.4 0.4
4 993 56.9 3.8 15.0
5 .10 0.16 0.21 0.8
6 .10 0.47 0.18 2.6
7a .1000 0.4 0.9 0.4
8 .1000 0.22 0.16 .1000 0.4 0.29 1.4 1.4
9 .1000 11 7.7 1.4
10a .10000 3800 580 6.6
11 .100 .100 .100 Na
12 .1000 58.3 3.38 17.2
13a .1000 90 45 2.0
14 .1000 148.8 48 3.1
15 .1000 107.7 27.1 4.0
16 .1000 77 2.5 30.8
17 259 1.5 0.8 1.9
18 .10 0.515 0.078 6.6
19 .10 0.39 0.18 2.2
20 .100 4.9 2.57 1.9
21 .1000 625 385 1.6
22 .1000 595 227 2.6
23 .100 8.4 .100 .100 10 .100 , 0.1 , 0.1
24a 7.8 2.2 3 0.7
aTransiently transfected cell lines; results were reported previously [78].
doi:10.1371/journal.pone.0091476.t002
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MeOH (v/v), treated with an ultrasonication rod (Bandelin,
Berlin, Germany) and extracted on a shaker for 30 min. After
centrifugation the biomasses were subsequently extracted using
80% MeOH (v/v). The 50% MeOH and 80% MeOH extracts of
the respective biomasses were combined and dried in vacuo. The
crude extracts were fractionated using water-methanol step
gradients on C18 cartridges on a VersaFlash system (supelco,
Bellefonte, USA), and the fractions containing MCs (monitored by
HPLC) were dried in vacuo. After reconstitution, these fractions
were subjected to semi-preparative HPLC. For a detailed
description of the isolation procedures see File S1. Microcystins
RR, LW, and LF and okadaic acid were obtained from Axxora,
LLC (San Diego, CA), and microcystins LR and YR were
obtained from Sigma-Aldrich (St. Louis, MO).
Structure elucidation
The structures of the isolated MCs have been determined by
high-resolution tandem mass spectrometry [51,52,84], and con-
firmed by one- and two-dimensional NMR spectroscopy. Samples
for NMR spectroscopy were dissolved in 600 mL d6-DMSO.
NMR spectra were recorded at 600 MHz (1H frequency) on a
Bruker AV-III spectrometer using cryogenically cooled 5 mm
TCI-triple resonance probes equipped with one-axis self-shielded
gradients. DQF-COSY spectra [90] were recorded using
20486512 complex data points using 8 scans. Spectra were
referenced indirectly to tetramethylsilane via the residual signals of
d6-DMSO (2.5 ppm for
1H). Tandem MS data have been
acquired using an HPLC coupled to an IT-TOF mass spectrom-
eter (Shimadzu Europe GmbH, Duisburg, Germany) with
electrospray ionization in positive mode and were evaluated using
the vendor’s software LCMSSolution version 3.60.361 with
Formula Predictor version 1.13. For the calculation of sum
formulae, the monoisotopic mass averaged from at least three
scans has been used. The compounds were separated on a Kinetex
C18 column (2.6 mm, 10063 mm, phenomenex, Torrance, USA)
using a gradient ranging from 5 to 80% CH3CN in water over 25
min (0.1% formic acid added as modifier). Precursor ions
corresponding to [M+H]+ were isolated in the ion trap,
fragmented by collision induced dissociation (CID) using argon
as collision gas (collision energy set to 150%, collision gas to 100%,
and q(Frequency) to 45.0 kHz), and separated in the TOF
analyzer. MS/MS scans were averaged and converted to the
mzXML format using the vendor’s software and evaluated using
the software mMass (calculated fragment ions: M, a, b, c, and z;
modifications: -H2O, -NH3, +CO, defined, combinations; match-
ing with a tolerance of 0.01 Da) [91]. Annotated tandem HRMS
and 1H-NMR spectra of all isolated compounds can be found in
File S2.
Cell lines and cytotoxicity assays
Primary hepatocytes are not suitable for studying microcystin
toxicity and transport, as OATP transporters are downregulated
within hours upon placing cells in culture [92]. Thus HeLa and
RKO cell lines were obtained from ATCC and transfected with
expression vectors for OATP1B1 and OATP1B3. Individual
clones were isolated by a limiting dilution, and isolated clones
showing high levels of expression by PCR were further charac-
terized as previously described [72,93]. Individual HeLa and
RKO clones were selected for further study by demonstration of
increased uptake [3H]-BQ123, a substrate for both transporters.
Further, the OATP1B3 clones demonstrated increased uptake of
[3H]-CCK-8, a specific substrate for OATP1B3 but not
OATP1B1, while the OATP1B1 clones did not show uptake of
[3H]-CCK-8. In addition, RKO and HeLa cells stably transfected
with an empty expression vector were used as controls. For
cytotoxicity assays, the cells were plated in triplicate in 96-well
microtiter plates in a medium containing 5% fetal bovine serum at
densities of 1000 cells/well. After 24 hours, medium containing
MC structural variants was added to the cells. After another 3
days, cell survival was determined with a sulforhodamine-based
assay as we have previously described [93–95]. As the dose
response curves for the apoptosis causing microcystins are steep
and go down to 0 within 72 hours, the sulforhodamine assay is
indicative of cell death [72,93]. The IC50 was calculated from the
dose response curve as the concentration of drug that produced a
50% decrease in the mean absorbance compared to the untreated
wells and reported as the average of at least three independent
determinations performed in triplicate using Prism software.
Supporting Information
File S1 Details on the Isolation of the Microcystin Congeners.
(PDF)
File S2 Annotated tandem HRMS and 1H-NMR spectra of all
isolated compounds. Raw NMR and MS data of these compounds
are available free of charge via the Internet at http://dx.doi.org/
10.6084/m9.figshare.880755.
(PDF)
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